We demonstrated that Tregs enhance their binding with CD29 under MASLD conditions, and CD29, in turn, enhances Treg‐mediated tumour cell adhesion and EMT induction, driving the malignant progression from MASH to HCC. The gene discussed is ITGB1; the disease is neoplasm.